# A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

> **NCT03833128** · PHASE1 · COMPLETED · sponsor: **Reneo Pharma Ltd** · enrollment: 24 (actual)

## Conditions studied

- Fatty Acid Oxidation Disorders

## Interventions

- **DRUG:** Low Dose REN001
- **DRUG:** High Dose REN001

## Key facts

- **NCT ID:** NCT03833128
- **Lead sponsor:** Reneo Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-03-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833128, "A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03833128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*